AKT1 and breast cancer: BC tumor cells with PIK3CA mutations had lower probability of early apoptosis after being treated with epirubicin, and abnormal protein expression in PI3K-AKT signaling pathway, suggesting the association between chemotherapy resistance and activated PI3K-AKT pathway in TNBC (39).